Background-Although coronary angiograms after bare-metal stent (BMS) implantation show late luminal narrowing beyond 4 years, the detailed changes inside the BMS have not yet been fully elucidated. Methods and Results-Serial angiographic and angioscopic examinations were performed immediately (baseline), 6 to 12 months (first follow-up), and Ն4 years (second follow-up) after stenting without target lesion revascularization in 26 segments of 26 patients who received BMS deployment for their native coronary arteries. Angioscopic observation showed atherosclerotic yellow plaque crushed out by stent struts in 22 patients (85%) and mural thrombus in 21 patients (81%) at baseline. At first follow-up, white neointimal hyperplasia was almost completely buried inside the struts, and both yellow plaque and thrombus had decreased in comparison with baseline (12% and 4%, respectively; PϽ0.001). The frequencies of yellow plaque and thrombus increased from the first to second follow-ups (58% and 31%, respectively; PϽ0.05). All of the yellow plaques in the second follow-up were located not exterior to the struts but protruding from the vessel wall into the lumen. Late luminal narrowing, defined as an increasing of percent diameter stenosis between the first and second follow-ups, was greater in segments with yellow plaque than in those without yellow plaque (18.4Ϯ17.3% versus 3.6Ϯ4.2%, respectively; Pϭ0.011).
T wo randomized trials revealed that implantation of metallic coronary stents, so-called bare-metal stents (BMS), reduces the incidence of restenosis compared with the plain ordinary balloon angioplasty. Therefore, BMS are widely used in interventional cardiology. 1, 2 Several clinical follow-up studies have demonstrated the medium-to longterm efficacy and safety of BMS for coronary artery revascularization. [3] [4] [5] [6] [7] Angiographic examinations evaluated serial changes in thickness of neointimal hyperplasia as lumen loss or diameter stenosis within the BMS segment by quantitative coronary angiography (QCA). 3, 8 The luminal narrowing of the BMS segment commonly progresses for up to 11 years after an improvement of luminal narrowing between 6 months and 3 years. 3, 8 Although the long-term clinical outcome of the BMS segment is considered generally favorable, the luminal narrowing presenting with restenosis of the BMS is significantly associated with clinical events such as myocardial infarction during extended follow-up periods. 9 A previous angioscopic study on the 3-year follow-up after BMS implantation showed that nontransparent white neointima changes into transparent from 6 months to 3 years, and this phenomenon of neointimal alternation therefore plays a major role in the improvement of luminal narrowing during the period. 10 However, the mechanisms for the late luminal narrowing over 3 years are not elucidated. Full-color and 3-dimensional angioscopic images of the coronary lumen provide detailed information on the vessel walls, including the stent segment and atherosclerotic process beyond angiography. [11] [12] [13] [14] [15] [16] Therefore, further neointimal transformation may continue over a 3-year period. Serial angioscopic observation focusing on the features inside the BMS was performed to validate the qualitative changes over an extended period (Ն4 years) after their implantation.
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Methods
Patient Selection
Between February 2007 and December 2008, repeat angiographic and angioscopic examinations after an extended period (Ն4 years) as second follow-up was performed for 27 patients who underwent previous angioscopic examinations with good image quality immediately and 6 to 12 months after successful BMS implantation (baseline and first follow-up, respectively) in their native coronary arteries without target lesion revascularization. We reported the results of 6-month follow-up of 12 of 27 patients. 16 To estimate the natural process of the initial stenting without mechanical injury by repeat angioplasty, the patients that received target lesion revascularization before the second follow-up were excluded from the study. In addition, patients or lesions were excluded if they presented (1) cardiogenic shock or unstable hemodynamic state, (2) low ejection fraction of the left ventricle (Ͻ30%), (3) chronic renal failure (serum creatinineՆ2.5 mg/dL) without regular hemodialysis, (4) restenotic lesion, (5) lesions of coronary bypass grafts, (6) left main coronary artery disease or ostial lesions, and (7) tortuous vessels or heavily calcified vessels proximal to the target lesions. The last 2 criteria were instituted because of the expected difficulty in acquiring angioscopic images for entire stent segments. All of the patients provided informed consent for the procedure, which was approved by the institutional review board.
Clinical Demographics
The patient demographics, including information on coronary risk factors and prescription, were obtained by a hospital chart review. Acute coronary syndrome was defined as the group of clinical symptoms, electrocardiographic changes, and elevation of cardiac biomarkers that is compatible with acute myocardial infarction and unstable angina. 17 Stable coronary artery disease was defined as a positive stress test and no change in frequency, duration, or intensity of chest symptoms within 4 weeks. Culprit lesions of ischemic heart disease (target lesions of the stenting) were identified by a combination of electrocardiographic findings, wall motion abnormalities of left ventricle, and angiographic lesion morphology.
Angiographic Analysis
Coronary angiograms were analyzed with a computer-assisted, automated edge detection algorithm (CMS, MEDIS, Nuenen, The Netherlands) by an expert angiographer blinded to clinical and angioscopic findings by QCA. The reference vessel diameter (mm), minimum lumen diameter (mm), and diameter stenosis (%) were measured at baseline and at first and second follow-ups. The minimum lumen diameter and diameter stenosis for in-stent and in-segment (defined as the stent plus 10 mm proximal and 10 mm distal to the edge) were calculated. Late luminal narrowing (%) was defined as increasing of diameter stenosis between first and second follow-ups. In-stent restenosis was defined as a Ն50% diameter stenosis at each follow-up. Any angiographic abnormal findings, such as filling defect, haziness, or lumen irregularity, were qualitatively evaluated using the standard definitions.
Coronary Angioscopic Imaging
Entire stent segments were observed with angioscopic catheters (Vecmova, Clinical Supply, Gifu, Japan or Vecmova Neo, Fib-erTech, Chiba, Japan) according to the procedure described. 16 Before performing the observations, the white balance was adjusted for color correction. During angioscopic observation, an exclusive assistant adjusted the light power to avoid reflection and maintain a regular degree of brightness on the view. Angioscopic images and the exact position of the angioscopic catheter on fluoroscopy during angioscopic observations were recorded on digital videotape for later analysis (Figure 1 ).
Definition and Analysis of Angioscopic Findings
A white membranous structure was defined as neointimal hyperplasia. Struts of implanted stent were classified as visible or invisible, and struts covered by transparent neointima or uncovered were classified as visible. 10 A yellow plaque was defined as a nonmobile, elevated yellow mass that could be clearly demarcated from the adjacent normal vessel wall or neointima of white color. 12, 18 The dominant location of the yellow plaque was classified as outside the stent (crushed out by the stent struts) or inside the stent (protruding from the vessel wall into the lumen) based on the 3-dimensional angioscopic images. The surface of the lumen or plaque was divided into smooth (simple) or irregular (complex) based on its morphology. In addition, surface irregularity was classified as a flap, fissure, or ulceration. 13 A thrombus was defined as a coalescent red, white, or mixed (red and white) structure, but clearly a separate structure that continuously remained despite complete removal of blood with a flush (Figure 1 ). 18 Intraobserver agreement on the angioscopic images was measured by having an observer repeat assessment of 50 images (presented in random order) after 1 week. Interobserver agreement was measured by comparing the assessment of 50 images by 2 observers blinded to clinical information including times of the angioscopic examinations. The intraobserver agreements for evaluated angioscopic items A, Image mixture system of fluoroscopy and angioscopy displays the 2 images on the same screen and it shows the precise positions of angioscopic images (black arrow) and implanted BMS (white arrows). B, Immediately after BMS implantation, yellow plaque and red thrombus crushed out by the stent struts are seen. They are located outside the stent struts. C, At the first follow-up, nontransparent white neointima completely covers over the stent struts. The stent struts are invisible, and the lumen surface is smooth. D, At the second follow-up, irregular yellow plaque (blue arrow) is obviously protruding from the surrounding white intima into the lumen, and the plaque is accompanied with red thrombus (white arrow). The stent struts are invisible. E, A yellow plaque is seen around the visible struts (white arrow) at the second follow-up. The plaque is clearly protruding from the struts. In this case, yellow plaque and visible struts simultaneously exist in the BMS segment. A white arrowhead indicates a guide wire.
(visible stent struts, yellow plaque, location of the yellow plaque, flap, fissure, ulceration, and thrombus) were 98%, 96%, 100%, 92%, 90%, 92%, and 98%, respectively. Interobserver agreements of those items were 94%, 94%, 98%, 86%, 88%, 90%, and 96%, respectively. If no consensus was achieved concerning the angioscopic items, then a third observer assessed them.
Clinical Follow-Up
Regular clinical follow-up visits of our hospitals occurred every month or every other month for up to the second follow-up. Dual antiplatelet therapy, ticlopidine added to aspirin, was continued for the first follow-up if there were no major side effects. At the time of first follow-up, neither clopidogrel nor glycoprotein IIb/IIIa had been approved for clinical use in Japan. Coronary risk factors were controlled by lifestyle modification and optimal medical therapies for secondary prevention of cardiovascular disease. The systolic and diastolic blood pressure (mm Hg), and serum levels of hemoglobin A1c (%), low-density lipoprotein (LDL) cholesterol (mg/dL), and C-reactive protein (mg/dL) were measured at the second follow-up.
Statistical Analysis
Data are presented as meanϮSD. Categorical variables are presented as frequencies, and they were analyzed by Fisher exact test. Continuous data were tested by Student t test to compare different categories. A P value Ͻ0.05 was considered statistically significant.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Patients Characteristics
Among 27 patients, good angioscopic images within the stent segment were not obtained in 1 patient because of delivery failure of the angioscopic catheter caused by a progressive stenotic lesion proximal to the target segment. Finally, 26 stent segments in 26 patients were therefore enrolled. The durations of the first and second follow-ups were 7.1Ϯ2.7 (6.0 to 11.9) months and 94.7Ϯ34.2 (48.2 to 129.6) months, respectively. The patient characteristics at baseline are shown in Table 1 
Serial Changes in the Angioscopic Findings
The angioscopic procedure was performed for all patients without major complications. Serial changes in angioscopic findings are shown in Table 2 and Figure 2 . The visible struts decreased from baseline to the first follow-up (PϽ0.001) by neointimal growth over the struts, and they increased at the second follow-up (Pϭ0.03 versus first follow-up). At baseline, all of the yellow plaques were dominantly located outside the stent. At the first follow-up, smooth white Values are n (%).
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neointima buried the majority of lumen, and yellow plaque decreased (PϽ0.001 versus baseline). Surface irregularity completely disappeared (PϭNS versus baseline), and residual red thrombus was seen in only 1 case (PϽ0.001 versus baseline). At the second follow-up, 15 yellow plaques were protruding from the vessel walls (visible struts or white neointima) into the lumens. The frequencies of yellow plaque, surface irregularity, and thrombus increased from the first follow-up to the second follow-up (PϽ0.001).
Clinical Factors and Angioscopic Findings of Extended Follow-Up
The study patients were divided into patients with (nϭ15) and without (nϭ11) yellow plaque within the BMS segment based on the angioscopic findings of the second-follow-up ( Table 3 ). The coronary risk factors, prescription, blood pressure, and profiles of blood examination including hemoglobin A1c and LDL cholesterol did not differ significantly between the 2 groups. The duration between stent procedure and the second follow-up was also similar between the 2 groups. The frequency of administration of oral hypoglycemic agents tended to be higher in patients with yellow plaque than in those without yellow plaque. The frequencies of yellow plaque at baseline and a visible stent at the second follow-up did not differ between the 2 groups. During the follow-up, 3 patients (2 with yellow plaque and 1 without yellow plaque) underwent stent implantation in progressive lesions remote from the targets of this study.
Angiographic Luminal Change and Angioscopic Findings of Extended Follow-Up
In-stent minimal lumen diameter and diameter stenosis were 2.83Ϯ0.41 mm and 11.7Ϯ5.2% for baseline, 2.37Ϯ0.39 mm and 24.4Ϯ13.3% for the first follow-up, and 1.96Ϯ0.52 mm and 36.5Ϯ18.7% of the second follow-up, respectively. Insegment minimal lumen diameter and diameter stenosis for them were 2.78Ϯ0.40 mm and 13.0Ϯ4.9%, 2.75Ϯ0.42 mm and 12.0Ϯ12.1%, and 2.80Ϯ0.41 mm and 9.6Ϯ8.7%, respectively. The comparative QCA data of the BMS segments with (nϭ15) and without (nϭ11) yellow plaque are shown in Table 4 . The minimal lumen diameter and diameter stenosis did not differ between the 2 groups at each phase of baseline, first, and second follow-ups. At the second follow-up, new in-stent restenosis was found in 3 segments with yellow plaque in 3 patients. Two patients had clinically driven target lesion revascularization resulting from restenosis. An angiographic abnormality was observed in 2 stent segments as lumen irregularity at the second-follow-up, and these segments contained complex yellow plaques and red thrombi identified by angioscopy. Late luminal narrowing was significantly larger in segments with yellow plaque than in those without yellow plaque (18.4Ϯ17.3% versus 3.6Ϯ4.2%, respectively; Figures 3 and 4 ).
Discussion
The present extended long-term (Ն4 years) angiographic and angioscopic follow-up after BMS implantation demonstrated that (1) vulnerable atherosclerotic plaque containing thrombus usually healed within 1 year after BMS implantation, and (2) neointimal proliferation is an active process in which white neointima may be transformed into lipid-laden yellow plaque with progressive late luminal narrowing. In this study, the majority of the BMS was buried into nontransparent white neointima, and complex yellow plaque and thrombus crushed out by stent struts almost completely disappeared from the view of angioscopy within a year. These angioscopic findings from baseline to the first follow-up indicate vascular healing response and clinical stability of the BMS segment. 10, 14, 16 A medium-term angiographic and angioscopic follow-up study by Asakura et al 10 revealed that in-stent neointimal thickness in QCA analysis decreased, and Values are meanϮSD or n (%). PϭNS between segments with and without yellow plaque for each phase. Late luminal narrowing, defined as an increasing of the percent diameter stenosis between the first and second follow-ups, is greater in segments with yellow plaque than in those without yellow plaque.
nontransparent neointima on angioscopy became partially transparent without any thrombus formation between 6 months and 3 years. In the same study, stent struts were in angioscopically visible condition in 58% of patients through the transparent neointima at 3 years, and they speculated that decrease in cell number and modification of histological composition caused by apoptosis invite quantitative and qualitative changes of neointima such as neointimal remodeling with thinning and transparency. 10, 19 Another pathological analysis of long-term coronary stenting showed the infiltration of macrophages with strong collagen-degrading matrix metalloproteinase into the neointima. 20 Degeneration of collagen in the neointimal layer by active macrophages may also help the neointimal remodeling. In the current series, 42% of the patients had visible struts of the BMS at the second follow-up. These results suggest that transparent neointima within the BMS segment partially persist for a long time.
Notably, yellow plaque protruding into the lumen was found in more than half the cases (58%) and was obviously localized inside the BMS. In addition, several yellow plaques appeared as complex morphology with irregular surface and were accompanied by intracoronary thrombi. A combination study with angioscopy and optical coherence tomography (OCT) showed that angioscopic yellow plaque was identical with lipidic fibroatheroma of OCT diagnosis with accurate tissue characterization in vivo. 20, 21 In fact, the lipidic component inside the BMS on cross-sectional OCT image was recognized as a yellow plaque in several cases ( Figure 5 ). Findings of complex yellow plaque containing thrombus, commonly observed in the culprit lesion of acute coronary syndrome, are characterized as angioscopic vulnerable plaque. 16, 22 Our observations emphasized that new formation of vulnerable atherosclerotic plaque with thrombus occurred between the first and second follow-ups. Although the phenomenon may sound strange, a postmortem pathological study demonstrated that prominent infiltration by lipid-laden macrophages into the neointima, and adherent thrombus, were found on disrupted lumen Ն4 years after BMS placement. 23 Moreover, specimens obtained by directional coronary atherectomy from new in-stent lesions Ͼ5 years con- tained thrombus and atherosclerotic components, such as cholesterol clefts, necrotizing foam cells, and inflammatory cells, facing on the healed neointimal layer. 24 These pathological findings support the current angioscopic findings of atherosclerotic plaque and thrombus formation in healed neointimal tissue inside the BMS over an extended long-term follow-up. One third (5 of 15) of segments with yellow plaque simultaneously had visible stent struts. The visible struts indicate regression of neointima, and the yellow plaque as progression of atherosclerotic neointima were occasionally seen in the same stent segment. Although the healing response accompanied by white neointimal proliferation at 6 to 12 months was homogeneous, the vascular response beyond 4 years perhaps is heterogeneous.
Regarding the potential mechanisms of atherosclerotic transformation inside the BMS segment, so far few interpretations have arisen. One is that stainless steel of the BMS evokes a remarkable foreign-body inflammatory reaction to the metal, and peri-stent chronic inflammatory cells may accelerate new atherosclerotic changes. 23 Another explanation is that uncertain factors independent of the peri-strut inflammation might trigger atherosclerotic change. 24 The current comparative data at the second follow-up failed to show determinant factors in appearance of the yellow plaque. Remarkably, atherosclerotic progression on angioscopy was confirmed, despite a good control for secondary prevention by optimal medical therapies. The concept that circulating LDL cholesterol plays a key role in the development of atherosclerotic disease has been established. In addition, previous angioscopic examination showed that the level of serum LDL cholesterol is strongly linked with atherosclerotic progression or regression. 12 This study, however, implies that development of atherosclerosis inside the BMS may have less association with LDL cholesterol, and its mechanisms may differ from those of nonstent segments in native coronary arteries.
Serial angiographic evaluations after the BMS implantation revealed a triphasic luminal response characterized by an early narrowing phase over 6 months, a medium-term regression phase from 6 months to 3 years, and a late narrowing phase beyond 4 years. 8 Although the current data lacked a QCA analysis at the 3-year follow-up, a similar change of luminal narrowing between the first and second follow-ups within the BMS segment was observed. It is understood that early luminal narrowing and medium-term regression are attributed to neointimal thickening by proliferation and thinning by neointimal remodeling, respectively. 10 This study showed that late luminal narrowing was significantly greater in segments with yellow plaque than in those without yellow plaque. Therefore, subsequent neointimal remodeling as yellow plaque formation toward the lumen may bring progressive late luminal narrowing. Although a compensatory enlargement or positive remodeling in the early stage of atherosclerosis occurs to maintain the lumen size of native coronary arteries, 25 atherosclerotic progression inside the stent segment may directly bring the late luminal narrowing observed on angiography. Although most of the patients with yellow plaque were clinically silent, vulnerable yellow plaque and thrombus with advanced luminal narrowing in the BMS segment may be one potential cause of adverse clinical events such as very late stent thrombosis during extended follow-up.
Limitations
This study population was relatively small, and any significant factors associated with atherosclerotic progression in the BMS segment could not be determined. In addition, patients who received target lesion revascularization during the follow-up were excluded for viewing the natural course of the initially placed BMS. Therefore, adverse clinical events related with severe restenosis of the BMS segment were uncertain. However, angioscopy showed detailed features inside the BMS beyond angiography alone, which allowed complete serial long-term observations. Most of the BMS were implanted for sealing of yellow plaque at baseline, and there were accidentally no diabetic patients treated with insulin injection. Further studies of a large number of patients are necessary to clarify the vascular response in different plaque characteristics and in relatively severe diabetic patients. In this study, various kinds of BMS were evaluated. Although the difference in the vascular response to the BMS is unclear, all of the BMS were made from stainless steel. Finally, angioscopic examinations were only performed for the stent segments. Therefore, the precise atherosclerotic progression of the nonstent segments in the patients could not be clearly elucidated.
Conclusions
Serial angioscopic observations of the feature inside BMS demonstrated that a white appearance mainly occupied by the neointima at 6-to 12-month follow-up often changed to a partial yellow and red lumen composed of atherosclerotic plaque and thrombus beyond 4 years. This atherosclerotic transformation from the healing response to the BMS may therefore be associated with late luminal narrowing on the findings of angiography.
